News – Page 357 – Endpoints News

AstraZeneca axes license agreement with Aridis, placing Europe-funded PhIII on hold

3 years ago

European investment group closes €260M raise for dementia fund

3 years ago

FDA lifts partial hold on Blueprint's CDK2 inhibitor

3 years ago

Biomea goes for $125M offering after early diabetes data nearly doubled stock price

3 years ago

Vanda wins court case against FDA over disclosure of CRL details for sleep drug

3 years ago

Ohio attorney general sues several PBMs over antitrust concerns

3 years ago

House committee chair requests info from FDA on funding for trials involving 'viral manipulation'

3 years ago

Pharma ad total tops $8B again in 2022, led by top brands from Sanofi and Regeneron, AbbVie

3 years ago

FDA plans upcoming adcomms for OTC contraceptive, epinephrine nasal spray, Intarcia's last shot

3 years ago

House committee to investigate FDA's response to ongoing drug shortages

3 years ago

Q&A: Pfizer corporate communications chief Sally Susman discusses book crafted in pandemic and personal lessons

3 years ago

MarketingRx roundup: AbbVie drives endometriosis awareness; Novartis adds to Cosentyx campaign

3 years ago

Ferring closes key research site, letting go 89 workers in San Diego

3 years ago

Biomea Fusion stock soars on early-stage diabetes data

3 years ago

Tiny multiomics biotech secures former J&J drug, new execs and new financing

3 years ago

Intra-Cellular Therapies gets a boost on PhIII depression drug data

3 years ago

Evotec’s CNS deal with Bristol Myers gets $50M infusion and eight-year extension

3 years ago

Private equity firm taps ex-Editas CEO Jim Mullen to help expand pharma portfolio — with a nod to cell, gene ...

3 years ago

Viking soars on early-stage weight loss data as it maps out PhII

3 years ago

Novartis rides with Bicycle for new pact on targeted radiotherapies

3 years ago

With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders

3 years ago

Gunning for 2023 approval, GSK details PhIII data for Jemperli in frontline endometrial cancer

3 years ago

AbbVie drops CytomX partnership, leaving PhII program in the air

3 years ago

Jeffrey Bluestone brings his startup haul to $400M+, joining forces with Regeneron on cell therapies

3 years ago

First page Previous page 354 355 356357358 359 360 Next page Last page